Cardiff: Second Half Of 2024 mCRC Data Is Major Inflection Point

howtogoto/iStock via Getty Images Cardiff Oncology, Inc. (NASDAQ:CRDF) is gearing up to report results from its phase 2 randomized CRDF-004 study, which is using its drug onvansertib + chemotherapy [Folfiri] + bevacizumab [Avastin] for the treatment of RAS-mutated metastatic colorectal cancer [mCRC] patients. This combination therapy of onvansertib is being compared to the current 1st-line standard of care [SOC] therapy chemotherapy + bevacizumab. The company is currently conducting this phase 2 randomized ...